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Abstract
Background: Tumor response to treatment has been generally assessed with anatomic and functional imaging. Recent
development of in vivo molecular and cellular imaging showed promise in time-efficient assessment of the therapeutic
efficacy of a prescribed regimen. Currently, the in vivo molecular imaging is limited with shortage of biomarkers and probes
with sound biological relevance. We have previously shown in tumor-bearing mice that a hexapeptide (HVGGSSV)
demonstrated potentials as a molecular imaging probe to distinguish the tumors responding to ionizing radiation (IR) and/
or tyrosine kinase inhibitor treatment from those of non-responding tumors.
Methodology/Principal Findings: In this study we have studied biological basis of the HVGGSSV peptide binding within the
irradiated tumors by use of tumor-bearing mice and cultured cancer cells. The results indicated that Tax interacting protein
1 (TIP-1, also known as Tax1BP3) is a molecular target that enables the selective binding of the HVGGSSV peptide within
irradiated xenograft tumors. Optical imaging and immunohistochemical staining indicated that a TIP-1 specific antibody
demonstrated similar biodistribution as the peptide in tumor-bearing mice. The TIP-1 antibody blocked the peptide from
binding within irradiated tumors. Studies on both of human and mouse lung cancer cells showed that the intracellular TIP-1
relocated to the plasma membrane surface within the first few hours after exposure to IR and before the onset of treatment
associated apoptosis and cell death. TIP-1 relocation onto the cell surface is associated with the reduced proliferation and
the enhanced susceptibility to the subsequent IR treatment.
Conclusions/Significance: This study by use of tumor-bearing mice and cultured cancer cells suggested that imaging of the
radiation-inducible TIP-1 translocation onto the cancer cell surface may predict the tumor responsiveness to radiation in a
time-efficient manner and thus tailor radiotherapy of cancer.
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Introduction
Radiation therapy, in addition to surgery and chemotherapy, is
one of the most commonly prescribed treatments for cancer
patients. However, due to the heterogeneity of tumors, not all the
tumors respond to a therapy regimen with a similar efficiency.
Certain tumors respond to one treatment regimen better than
others. The dose and delivery of treatments need to be tailored to
each individual patient and progression stage of the tumor [1].
With current assessment approaches that mainly detect the
treatment-related anatomic or histological changes within tumors
[2], it usually takes weeks to months before the therapeutic
response can be detected and the treatment efficacy can be
determined. The long clinical delay before a response can be
assessed costs patients valuable time on the expensive and
potentially ineffective treatments. A time-efficient assessment is
especially important in managing the highly malignant lung
cancer. For this reason, identification of specific biomarkers for the
early assessment of cancer response can help personalized cancer
therapy based on the cancer responsiveness to a prescribed
regimen.
Imaging the tumor-specific biomarkers has been investigated to
monitor the tumor response to treatment [3,4]. Proteomic and
genomic approaches enable new biomarkers discovery by profiling
the treatment-associated changes in the abundance of gene
transcripts or products [5,6]. Identification of tumor-specific
biomarkers with those approaches relies upon precise sampling
and thus requires time- and labor-consuming validations.
Compared to the proteomic or genomic techniques, phage display
is economic, flexible and easily executed. The in vivo phage display
technology [7] takes the advantage of high fidelity without
sampling bias and allows identifying the circulation-accessible
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spatial location instead of the expression abundance [8–10]. Over
the past decade, a myriad of phage display-derived peptides have
been generated to bind to tumor cells or tumor-associated antigens
[10–12]. Although phage display-derived peptides show promise
in the in vivo tumor targeting and molecular imaging of cancer, due
to a peptide’s small size and relatively low affinity to its molecular
target, it is still a great challenge to identify the molecular target
that contributes to the peptide binding in vitro and in vivo. Lack of
knowledge about the biological basis of the peptide binding within
tumors poses limitations on further development of the tumor-
binding peptides for clinical applications.
In a previous study, we have identified a small peptide
(HVGGSSV) that specifically binds to the tumors responding
positively to ionizing radiation and tyrosine kinase inhibitors by
using the in vivo phage display [13]. Here, we report that Tax
interacting protein 1 (TIP-1, also known as Tax1 binding protein
3, Tax1BP3) is a molecular target of the HVGGSSV peptide, and
the radiation-inducible translocation of the predominantly intra-
cellular TIP-1 protein onto the plasma membrane surface serves as
a biomarker for the tumor responsiveness to ionizing radiation.
Materials and Methods
Cell culture
Lewis Lung Carcinoma (LLC) and H460 lung carcinoma cells
were obtained from American Type Culture Collection (ATCC,
Rockville, MD, USA) and maintained in DMEM medium with
10% fetal calf serum (FCS) and 1% penicillin/streptomycin
(Thermo Scientific Inc., Waltham, MA). Primary human umbilical
vein endothelial cell (HUVEC) were obtained from Lonza
Biologics (Riverside, CA) and maintained in EGM endothelial
cell growth medium. Boyden chambers (Becton Dickinson
Labware, Franklin Lakes, NJ) were used to prepare co-culture of
HUVEC and cancer cells. Constructs expressing shRNA sequenc-
es with green fluorescent protein (GFP) were purchased from
Open Biosystems (Thermo Fisher Scientific, Huntsville, AL), the
TIP-1 specific shRNA (59-GGCTAACAGCTGATCCCAA-39)
matches with TIP-1 mRNA transcripts, a non-targeting sequence
was used as a control. Transfection of the cells with the
recombinant plasmids was conducted with standard protocols
[14]. Efficiency of the shRNA on knocking down of TIP-1
expression was detected by western blot analysis of whole cell
lysates. Cells were irradiated with 300 kV X-rays using a Pantak
Therapax DXT 300 Model X-ray unit (Pantak, East Haven, CT).
Antibodies and chemicals were purchased from Sigma (St. Louis,
MO) unless otherwise stated.
Phage Display
Screening [15,16] of a cDNA library displayed on T7
bacteriophages was employed to identify proteins interacting with
the HVGGSSV peptide. In brief, the peptide-immobilized
magnetic beads were prepared by incubating 10 ml of 2 mg/ml
biotin-GCNHVGGSSV-COOH peptide (Genemed Synthesis
Inc., San Antonio, TX) with 100 ml of streptavidin-coated
Dynabeads (Invitrogen, Carlsbad, CA) at room temperature for
30 minutes. The same amount of a scramble peptide (Biotin-
GCSGVSGHGN-COOH) served as a control in all rounds of the
screening. After removal of the free peptides, the beads were
resuspended in the phosphate buffered saline (PBS, pH 7.2)
containing 0.1% Tween 20 (PBST). The complex was incubated
with 10
9 plaque-forming units (pfu) of a T7Select human lung
tumor cDNA library (Novagen, Gibbstown, NJ) in PBS. The
mixture was incubated on a shaker for 2 hours at room
temperature. The phages bound to the beads were magnetically
separated from the unbound phages within solution. After the
beads were washed 5 times with PBST, the phages recovered from
the HVGGSSV peptide-coated beads were amplified in E.coli
BLT5615 (Novagen) for the subsequent rounds of screening. In
each round of the screening, 10
9 pfu of the amplified phage were
used. The phages recovered from both of the HVGGSSV peptide-
coated beads and the control beads were also titrated; selectivity of
the phages to the HVGGSSV peptide was estimated with the ratio
of the phages recovered from the target beads to those recovered
from the control beads. The screening was terminated till the
significant (.1000) selectivity of the phages to the target beads was
achieved.
The phages recovered from the last round of the screening were
cloned and amplified for the enzyme-linked immunosorbent assay
(ELISA)-based plate screening. Briefly, 96-well polystyrene plates
(Corning Corp., Lowell, MA) were sequentially coated with
streptavidin (0.2 mg/well), blocked with 2% BSA in PBS solution,
and incubated with the biotinylated HVGGSSV or scramble
peptides (50 ng/well). 50 ml of the amplified phages were added to
each well for 2 hours incubation at room temperature. After the
plates were washed five times with PBST, binding of the phages to
the peptides was detected with a rabbit antiserum against the T7
phage (a kind gift from Dr. Toshiyuki Mori at National Cancer
Institute, Frederick, MD) and a secondary antibody conjugated
with horse radish peroxidase (HRP) (Sigma). Following washing
with PBST and incubation with 100 ml of substrate solution
containing 2,29-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-
diammonium salt (ABTS, from Sigma) within 50 mM sodium
citrate buffer, optical density was measured at 405 nm. The insert
sequences of the HVGGSSV-specific phage clones were amplified
with polymerase chain reactions (PCR) by use of a forward primer
(59- GGAGCTGTCGTATCCAGTC-39) and a reverse primer
(59-TGGATTGACCGGAAGTAGAC-39). The PCR products
were purified for sequencing reaction by using a sequencing
primer (59-ATGCTCGGGGATCCGAATTC-39).
GST-TIP-1 protein production
cDNA encoding TIP-1 was amplified using PCR by use of the
selected phage clone as template. A construct encoding TIP-1
mutant with a dysfunctional PDZ domain (H90A) [17] in
pcDNA3.1 plasmid was a generous gift from Dr. Paul A. Welling
at University of Maryland (Baltimore, MD). The DNA fragments
encoding the functional TIP-1 and mutant TIP-1 were respec-
tively subcloned into a pGEX-4T-1 vector (GE Healthcare)
between BamH I and EcoR I sites to create fusion protein with
glutathione S-transferase (GST). The GST-fused proteins were
expressed in E.coli XL-10 GOLD (Stratagene, Kirkland, WA) and
purified to homogeneity by passing through a column packed with
GST-binding resin (Thermo Scientific Inc., Waltham, MA)[18].
The purified proteins were dialyzed against PBS and quantified
with the Bradford methods [19]. Size and purity of the proteins
were examined by SDS-PAGE.
Peptide binding assay
The ELISA was used to study interaction of the peptide with the
recombinant TIP-1 protein. All the biotinylated peptides were
synthesized at Genemed Synthesis Inc. (San Antonio, TX), purity
and molecular weight were assured with HPLC and mass
spectrometry. Corning costar 96-well microtiter plates with high
protein-binding capacity were coated with streptavidin (0.2 mg/
well in PBS) overnight at 4uC. Plates were blocked with BSA and
washed twice with PBST before incubating with the biotinylated
peptides (50 ng/well) at room temperature for 1 hour. After
TIP-1 Translocation
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1(H90A) proteins were added to each well (100 ng/well),
respectively. The recombinant proteins bound to the immobilized
peptides were detected by a rabbit anti-GST antibody and a
secondary antibody conjugated with HRP (Sigma). After washing
with PBST as described above, ABTS solution was added to each
well for color development, and optical density at 405 nm was
measured for quantification of peptide affinity to the recombinant
proteins.
Preparation of TIP-1 specific antibodies
New Zealand white rabbits (Harlan Laboratories, Prattville, AL)
were initially immunized with 100 mg of purified GST-TIP-1
protein premixed in a 1:1 ratio by weight with Titermax adjuvant
(CytRx Corporation, Los Angeles, CA). One month after the
initial immunization, the animals were boosted with same amount
of antigen twice with 2 weeks interval without the adjuvant. Blood
samples were periodically taken for antibody titration and
specificity analyses by ELISA or western blot. When the anti-
TIP-1 antibody reached the designated high titer, the animals
were sacrificed to collect the antiserum. The antiserum was
purified by passage through protein A plus protein G columns
(sigma) to purify IgGs. TIP-1 specific antibodies were prepared
from the purified IgGs by tandem absorption with bacterial
proteins and the purified GST protein-conjugated sepharose-4B
(Sigma) to remove the IgGs that might bind proteins other than
TIP-1. The final antibody was dialyzed against PBS and
concentrated via Amicon centrifugal filters (Millipore, Billerica,
MA). Specificity of the TIP-1 specific antibody was validated with
whole cell staining and western blot analyses of whole cell lysates.
All animal studies were conducted as approved (protocol ID: M/
08/051 and M/08/592) by the Institutional Animal Care and Use
Committee (IACUC) at Vanderbilt University.
Antibody competition assays
In vitro antibody competition experiments were performed using
the ELISA as described above in the peptide binding assay, except
that the purified GST-TIP-1 proteins were pre-mixed with serially
diluted antibodies (starting at 10 mg/ml) before incubation with
the immobilized peptides. In vivo antibody competition assays were
conducted as described [13]. In brief, 1610
6 LLC cells were
implanted subcutaneously in both hind limbs of C57BL/6 Foxn1
null/null nude mice (4,5 weeks old, Harlan Laboratories). The
tumors were allowed to grow to a size of 0.5 cm in diameter before
treatment with X-ray radiation (5 Gy) on one tumor while the
other tumor in the same mouse was used as an untreated tumor
control. All animals were anesthetized and shielded to only allow
irradiation of the tumors with 300 kV X-rays using a Pantak
Therapax DXT 300 Model X-ray unit (Pantak, East Haven, CT).
200 mg of TIP-1 antibody or control antibody (normal rabbit IgGs)
were injected through tail veins 4 hours after the radiation
treatment, then followed by injecting 100 mg of Alexa Fluor 750
(Invitrogen)-labeled streptavidin that was pre-complexed with the
biotinylated HVGGSSV peptides. Biodistribution of the peptide-
strepavidin complex within the tumor-bearing mice was moni-
tored with In Vivo Imaging Systems 200 (IVIS 200) (Caliper Life
Sciences, Hopkinton, MA) at the Vanderbilt University Institute of
Imaging Sciences 24 hours after the peptide injection.
Animal imaging
Tumor model development, tumor treatment and peptide or
antibody labeling with Alexa Fluor 750 (Invitrogen) were
conducted as described in previous publication [13]. 20 mgo f
the fluorochrome-labeled antibody or peptide were intravenously
administrated in each animal at 4 hours post irradiation. Optical
images were taken at 24 hours post the antibody injection with
Xenogen IVIS-200.
Flow Cytometry
Lung cancer cells LLC and H460, HUVEC, or HUVEC co-
cultured with either LLC or H460 (in a Boyden Chamber) were
allowed to grow to 80% confluency, and irradiated with 0, 2, 4, 6
or 8 Gy, respectively. At variable time points after the treatment,
the cells were detached with accutase (eBioscience, San Diego,
CA) and collected by centrifugation at 1006g for 5 minutes. The
TIP-1 antibody in PBS containing 2% BSA was added to the
suspended cells and incubated on ice for 40 minutes. Free TIP-1
antibody was removed by centrifugation and the cells were
resuspended with fresh PBS before Alexa Fluor 488-labeled goat
anti-rabbit antibody (Invitrogen) was added and incubated for
another 40 minutes on ice. Again the cells were washed and
Annexin V-APC (BD Biosciences, Franklin Lakes, NJ) was
incubated with the cells for 30 minutes on ice to detect apoptotic
cells, Propidium Iodide (PI, BD Bioscience) was added in the last
10 minutes to detect cell plasma membrane integrity. Cells were
scanned with a BD LSRII flow cytometer (BD bioscience).
TIP-1-positive and -negative H460 cells were sorted from the
PI-negative cell populations with the FACSAria (BD bioscience)
for proliferation and radiosensitivity assays. The cell proliferation
was surveyed with Ki-67 staining. Briefly, the sorted TIP-1 -
positive or -negative cells were cultured on glass coverslips at 37uC
for 24 hours. The cells were then fixed in 70% ethanol, permeated
with 0.5% Triton X-100, and stained with Ki-67 antibody (Vector
laboratories, Burlingame, CA). Cells were counterstained with
DAPI (49,6-diamidino-2-phenylindole) before examination under
fluorescence microscope. The susceptibility of the TIP-1-positive
and -negative H460 cells to ionizing radiation was evaluated with
a clonogenic assay in which the sorted cells were seeded and
cultured with DMEM medium supplemented with 10% FCS and
antibiotics in petri dishes for 4 hours before the cells were
irradiated with X-ray at variable doses. The colonies were allowed
to form in 12 days. The colonies were stained with methylene blue
solution and the colony numbers were counted for data analyses.
Statistical analyses
All data were analyzed with the Student’s t-test to determine
significance (with .95% confidence) of the differences. Results are
presented as mean 6 S.D.
Results
TIP-1 binds to the HVGGSSV peptide
We have previously shown that one phage display-derived
peptide HVGGSSV with the selective binding within a broad
spectrum of tumors including lung cancers that had been treated
with X-ray radiation and multiple tyrosine kinase inhibitors, the
peptide binding within the treated tumors correlated to the overall
efficacy of the treatment on the tumor growth control [13]. To
further develop this peptide for molecular imaging and tumor-
targeted drug delivery, we intended to identify the molecular
target that enables the selective binding of the HVGGSSV peptide
within irradiated tumors. Screening a T7 phage-displayed human
lung tumor cDNA library against the HVGGSSV peptide
revealed TIP-1 as one protein that enables the selective binding
pf the HVGGSSV peptide within irradiated tumors.
To identify the molecular target of the HVGGSSV peptide
within irradiated tumors, a T7 phage-displayed human lung tumor
cDNA library composed of 10
7 independent phage clones was
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onto magnetic beads. The beads with a scramble peptide were
used as a control to deplete the non-specific phage clones. The
phages recovered from the HVGGSSV peptide-coated beads, as
well those recovered from the control beads, were titrated by
following procedures as described [15,16]. After 5 rounds of such
screening, it was found that total phages showed more than 1000-
fold selectivity to the HVGGSSV peptide-coated beads over the
control beads (Fig. 1A), indicating the screening successfully
enriched some phage clones that selectively bind to the
HVGGSSV peptide. Single clones from the fifth round of the
biopanning were isolated for further ELISA-based plate screening.
Roughly 46.8% (22/47) of the analyzed phage clones exhibited
specific binding to the HVGGSSV peptide but no detectable
binding was observed to the control peptide which has same
amino acid composition but with a scrambled amino acid
sequence (data not shown). 17 out of the 20 (85%) sequenced
HVGGSSV-binding phage clones encoded amino acid sequence
of the TIP-1 [20]. Specificity of the TIP-1 expressing phages to
HVGGSSV peptide was shown (Fig. 1B) in the ELISA-based
assays.
TIP-1 binds to the HVGGSSV peptide via PDZ domain
To further study interaction of the HVGGSSV peptide and
TIP-1 protein, gene fragments encoding TIP-1 protein were
inserted into an expression plasmid to produce recombinant GST-
TIP-1 proteins in E. coli. The GST tag was utilized to purify the
recombinant proteins to homogeneity (Fig. 1D). Affinity of the
HVGGSSV peptide with TIP-1 protein was studied with the
ELISA by use of the purified recombinant proteins and synthetic
peptides (Fig. 1E). TIP-1 protein is a small protein of 124 amino
acids, a PDZ-domain is the only functioning structure identified so
far (Fig. 1C). The HVGGSSV peptide contains a canonical PDZ
binding motif (-X-S/T-X-V/L/I, whereas X represents any
hydrophobic amino acids) [21], the peptide probably binds to
TIP-1 through the PDZ domain. Therefore a TIP-1 mutant
protein (H90A) with abolished PDZ ligand binding capability [17]
was included in the binding assay. Several peptides with mutation
within the PDZ binding motif were also included in the ELISA-
based affinity study. The data showed that the HVGGSSV
peptide binds to the TIP-1 protein through the PDZ domain, it
can not bind to the H90A mutant which contains a dysfunctional
PDZ domain. The scramble peptide, as well as other peptides with
single mutation within the PDZ binding motif, did not show
significant binding to the TIP-1 protein (Fig. 1E).
TIP-1 specific antibody competes with HVGGSSV peptide
for TIP-1 binding
TIP-1 antibody was developed by immunizing rabbits with the
purified GST-TIP-1 proteins. Specificity and reactivity of the TIP-
1 antibody were determined by western blot analysis of whole LLC
cell lysate and immunofluorescent staining of LLC cells in which
TIP-1 expression had been depleted with specific shRNA. The
TIP-1 specific antibody only recognized a single band corre-
sponding to the endogenous TIP-1 protein (,14 kD) in a western
blot analysis of the LLC whole cell lysates, with minor or
undetectable binding to other unrelated proteins (Fig. 2A). Cell
staining further demonstrated specificity of the TIP-1 antibody.
We identified one out of a panel of shRNA constructs that
efficiently down-regulated TIP-1 expression within LLC cells, as
shown by western blot analysis of whole cell lysate (upper panel of
Fig. 2-B). This TIP-1 targeting shRNA was selected for
transfection of LLC cells and the transfection was tracked with
GFP expression from the shRNA plasmid. Overlapping of the
TIP-1 antibody (red) and GFP (green) was observed within the
LLC cells that were transfected with a construct with a control
shRNA (pointed with arrow heads). The TIP-1 specific antibody
did not stain the LLC cells that were transfected with a construct
with the TIP-1-targeting shRNA (pointed with arrows), because
the target of the antibody had been depleted with the TIP-1
targeting shRNA (lower panel of Fig. 2B). These data demon-
strated that the TIP-1 antibody did not bind to any protein other
than TIP-1 within the cancer cells. These results confirm that this
is a TIP-1 specific antibody.
The TIP-1 specific antibody inhibits the HVGGSSV peptide
binding to the recombinant TIP-1 protein in a dose-dependent
manner as measured by ELISA (Fig. 2C), whereas the control
antibody did not interfere with the binding. The results of these
experiments demonstrate that the TIP-1 specific antibody share or
overlap with the HVGGSSV peptide for a common interacting
areas within the TIP-1 protein. Therefore, this TIP-1 antibody
was used to study the contribution of TIP-1 to the selective binding
of the HVGGSSV peptide within irradiated tumors.
TIP-1 mediates binding of the HVGGSSV peptide within
irradiated tumors
To determine if TIP-1 binds to the HVGGSSV peptide within
irradiated tumors, antibodies were intravenously administrated in
LLC tumor-bearing mice prior to the injection of the fluorophore-
labeled HVGGSSV peptide. Optical imaging data showed that
binding of the HVGGSSV peptide within the irradiated tumors
was not affected by pre-injection of the control IgGs. However,
pre-injection of the TIP-1 specific IgGs dramatically attenuated
the accumulation of the fluorophore-labeled peptide within the
irradiated tumors (Fig. 2D). These data clearly demonstrated that,
at least in part, TIP-1 mediates the selective binding of the
HVGGSSV peptide within the irradiated tumors.
TIP-1 specific antibody exhibited similar binding patterns
as the HVGGSSV peptide within irradiated tumors
We have previously shown that HVGGSSV peptide specifically
binds to the tumors responding positively to radiation and/or
tyrosine kinase inhibitors [13]. If TIP-1 contributes to the peptide
accumulation within irradiated tumors, one logic prediction is that
the TIP-1 antibody can recapitulate the biodistribution pattern of
the HVGGSSV peptide in tumor-bearing mice. To test this
hypothesis, nude mice bearing H460 or LLC xenografts were
irradiated, Alexa Fluor-750 labeled TIP-1 antibody was injected
via tail veins 4 hours after the radiation treatment by following the
same protocol that was used to study the biodistribution of the
HVGGSSV peptide within tumor-bearing mice [13]. Optical
images acquired 24 hours after the antibody injection indicated
that the TIP-1 antibody had high selectivity to the irradiated
tumors, but not the untreated tumors or normal tissues in both of
the LLC and H460 tumor models (Fig. 3A). In this regard,
accumulation of the TIP-1 specific antibody within the irradiated
tumors was confirmed with immunohistochemical staining
(Fig. 3B) of the retrieved tumor tissues after animal imaging.
Radiation induces TIP-1 translocation onto the plasma
membrane surface
TIP-1 is a basically intracellular protein that is ubiquitously
expressed within multiple organs [22]. The tumor-specific and
radiation-inducible binding the HVGGSSV peptide and the TIP-1
antibody within tumor-bearing mice suggested that TIP-1 accessibil-
ity to the circulating peptide or antibody is inducible upon radiation
treatment and limited within tumor cells. We used cultured LLC,
TIP-1 Translocation
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TIP-1 translocation onto the cell surface. Western blot analysis of the
whole cell lysates did not show dramatic changes in the TIP-1 protein
level after IR in all the three tested cells (data not showed). However,
flow cytometric analysis showed that percentage of the H460 cells
with TIP-1 expression on the cell surface was elevated from basal
Figure 1. HVGGSSV peptide binds to PDZ domain of the TIP-1 protein. A: Enrichment of phages with selective binding to the HVGGSSV
peptide. Phages recovered from the five rounds of screening and those from the original phage library were subjected to selectivity analysis on beads
coated with the HVGGSSV peptide or a scrambled peptide control, respectively. Shown are number (PFU) of phages recovered from the beads after
the free phages were washed off. 10
9 PFU of phages were used in this assay. B: Specificity of the TIP-1-expressing phage to the HVGGSSV peptide.
C: Diagram of TIP-1 protein shows location of PDZ domain and the critical amino acid (H90) for PDZ ligand binding; D: SDS-PAGE image shows purity
of the recombinant TIP-1 proteins and a dysfunctional mutant TIP-1 (H90A). The fusion proteins (,37 kD) were analyzed along with molecular weight
markers. E: Relative association of the purified recombinant proteins to the synthetic peptides was evaluated with ELISA. In these assays, 100 ng of
the purified GST/TIP-1 or GST/TIP-1(H90A) proteins were used per wells, all the synthetic peptides were used as 50 ng per well. The mutations in the
PDZ binding motif were underlined. Shown are representative data from triplicate experiments. * p,0.05, n=3, the Student’s t-test.
doi:10.1371/journal.pone.0012051.g001
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treatment (Fig. 4A). This observation was supported by immunoflu-
orescent staining of the surface-located TIP-1 on the irradiated H460
cells (Fig. 4B). It was found that the translocation of the TIP-1 protein
onto the H460 cell plasma membrane surface sustained for a
prolonged period of time after the irradiation (Fig. 4C). The effect of
IR on TIP-1 translocation is dose-dependent (Fig. 4D), higher dose of
IRwasmoreeffectivelyinducingtheTIP-1translocationontothecell
Figure 2. TIP-1 specific antibody blocked the HVGGSSV peptide binding within irradiated tumor. A: Specificity of the TIP-1 antibody as
revealed with western blot analysis of whole LLC cell lysate. The endogenous TIP-1 protein (,14 kD) recognized by the antibody was pointed with
arrow. B: Specificity of the TIP-1 antibody as demonstrated in immunofluorescent staining of LLC cells that were transfected with shRNA plasmids.
Effect of the TIP-1 targeting shRNA on TIP-1 expression was determined with western blot analysis (upper panel). In the cell staining, the transfected
cells were tracked with GFP protein expression from the shRNA plasmids. TIP-1 was stained as red with the TIP-1 antibody. Cell nuclei were stained
with DAPI. The LLC cells transfected with the control shRNA that did not affect TIP-1 expression were pointed with arrow head, while the cells
transfected with TIP-1 targeting shRNA that abolished TIP-1 expression were pointed with arrows (lower panel). C: ELISA-based in vitro competition
assay. Serially diluted antibodies were respectively pre-incubated with the purified GST/TIP-1 proteins (100 ng/well) before the complex was addedt o
the plates coated with the HVGGSSV peptide (50 ng/well). The GST/TIP-1 protein associated to the immobilized HVGGSSV peptide was detected with
GST-specific antibody. D: Optical images of LLC tumor-bearing mice that were co-administrated with the Alexa Fluor 750-labeled HVGGSSV peptide
and antibodies. LLC tumors in the left hind limbs were irradiated at 5 Gy (pointed with arrows). 200 mg of the TIP-1 antibody, or the control antibody,
was injected at 2 hours post the IR treatment, followed by injection of Alexa Fluor 750-labeled HVGGSSV peptide at 4 hours post the IR treatment.
Optical images were acquired 24 hours after the peptide injection. The presented data represent three independent experiments.
doi:10.1371/journal.pone.0012051.g002
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cell surface were also observed on the LLC cells, but not the HUVEC
cells even the endothelial cells had been co-cultured with LLC or
H460 cancer cells (Fig. 4F). These data suggested that radiation
induced translocation of the intracellular TIP-1 onto the plasma
membrane might be limited to cancer cells.
Figure 3. TIP-1 specific antibody was selectively homed to the irradiated tumors. A: NIR images of the TIP-1 antibody distribution within
tumor-bearing mice. H460 and LLC tumors were developed in hind limbs of nude mice, respectively. Tumors were indicated within the dashed circles.
The irradiated tumors (at 5 Gy) were pointed with arrows. Alexa Fluor 750-labeled control or TIP-1 specific antibodies were injected 4 hours after the
irradiation. The showed representative optical images were acquired 24 hours after the antibody injection. B: Immunohistochemical staining of the
intravenously administrated antibodies within the irradiated tumors. The imaged tumors were retrieved for detection of the antibodies within the
tumors. The antibodies (rabbit IgGs) were detected with HRP-conjugates and visualized with DAB (shown as brown). Hematoxylin (blue) was used for
counterstaining. Representative images from H460 tumor sections were presented, high magnification (x400) images were shown as inserts.
doi:10.1371/journal.pone.0012051.g003
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PLoS ONE | www.plosone.org 7 August 2010 | Volume 5 | Issue 8 | e12051Figure 4. Radiation induced TIP-1 translocation onto the plasma membrane of the cancer cells. A: Flow cytometric profile of TIP-1
expression on the H460 cell surface. TIP-1 on the cell surface was detected with the TIP-1 antibody 24 hours after radiation treatment, a control IgG
was included to demonstrate the antibody specificity. B: Fluorescent staining of the TIP-1 expression (green) on the cell surface of the irradiated H460
cells. DAPI was used for counterstaining. C: Time course study. The H460 cells were irradiated at 5 Gy and then fixed at variable time points after
irradiation for flow cytometric analysis of the TIP-1 expression on the cell surface. Percentage of the TIP-1 positive cells was presented. D: The dose-
dependence study. The H460 cells were irradiated with variable dose of X-ray, the cells were fixed 24 hours post the irradiation for profiling the TIP-1
expression on the cell surface with flow cytometry. Fold change of the TIP-1 positive cells was calculated by comparison to the untreated cells
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western blot analysis to determine whether they represent two
independent subgroups of cells with different TIP-1 protein level.
The result showed that the total TIP-1 levels were similar in both
of the TIP-1 positive and negative cells (Fig. 4E). Combining with
the observations that IR did not significantly change overall TIP-1
protein levels in the tested cells, we concluded that radiation does
not alter total protein levels of TIP-1 but rather appears to
promote the TIP-1 translocation onto the plasma membrane
surface.
The radiation-induced TIP-1 translocation relates to the
reduced colony formation and proliferation potentials
and the increased susceptibility to subsequent radiation
treatment
Annexin V profiling (apoptosis) and PI staining (membrane
integrity and cell death) are commonly used to detect cellular
response to cytotoxic treatment. H460 cells were irradiated (5 Gy)
and dissociated 24 hours after the irradiation for flow cytometric
analysis. Triple color flow cytometric profiling showed that
majority of cells with TIP-1 expressed on the cell surface (TIP-1
positive cells) are negative for both of the dead cell marker (PI) and
the apoptotic cell marker (Annexin V) (Fig. 5A). Among the total
apoptotic cells (0.48%+1.41% =1.89%), only one third (0.48%
out of 1.89%) of them were stained as TIP-1 positive. Among the
TIP-1 positive cells (13.5%+0.48%=13.98%), majority (13.5%
out of 13.98%) were Annexin V negative. Among all the dead cells
(0.98%+6.19%=7.17%), only small portion (0.98% out of 7.17%)
of the dead cells were stained as TIP-1 positive. Among all the
TIP-1 positive cells (13%+0.98%=13.98%), majority (13% out of
13.98%) were PI-negative. These data suggested that radiation-
inducible TIP-1 translocation onto the cell surface does not
overlap with the treatment associated apoptosis or cell death.
The TIP-1 positive and negative H460 cells were sorted from
the irradiated H460 cells for in vitro colony formation, proliferation
and radiation susceptibility studies. Although both of irradiated
TIP-1 positive and negative cells showed very low capability to
form visible colonies on petri dishes, statistical significance was
observed between the two subgroups of cells in respect of the
capability of colony formation (Fig. 5B). Ki-67 staining (Fig. 5C)
further showed that fewer TIP-1-positive cells were undergoing
proliferation than the TIP-1-negative cells. Clonogenic assays
(Fig. 5D) indicated that fewer TIP-1 -positive cells survived after
subsequent radiation treatment than the TIP-1 -negative cells. All
these data suggested that the radiation-inducible TIP-1 transloca-
tion onto the cancer cell surface serve as a biomarker for
identifying radiation-responding cancers before the onset of
apoptosis and cell death.
Discussion
Not all tumors, not even within the same classifications, respond
to a treatment in a same way. Personalized or tailored treatment of
tumor calls for efficient and reliable assessment of the tumor
responsiveness. Even though anatomic and functional imaging
have been extensively investigated and applied to assess tumor
response to treatment, new biomarkers with sound biological
relevance are still needed to assess tumor response to treatment in
a time-efficient manner.
In an effort to identify such biomarkers, we previously identify
a short peptide (HVGGSSV) with in vivo phage display
technology. The peptide demonstrated potentials in assessing
the tumor responsiveness to radiation and tyrosine kinase
inhibitors at the early stage of treatment courses [13]. As
demonstrated within multiple heterotopic and orthotopic tumor
models, the peptide selectively binds to the responding tumors,
the peptide accumulation within the treated tumors correlates to
the overall biological effects of the treatment on the tumor growth
control. In this study, TIP-1 was identified as one molecular
target of the HVGGSSV peptide. TIP-1 specific antibody
competed with the HVGGSSV peptide for binding within
irradiated tumors, and exhibited similar binding patterns as the
peptide in tumor-bearing mice. It was further identified that
radiation induced translocation of the basically intracellular TIP-
1 protein onto the cell surface in a dose-dependent manner. The
treatment-induced TIP-1 expression on the cell surface is
detectable in the first few hours after the treatment and before
the onset of treatment associated apoptosis or cell death. In fact,
majority of the cells expressing TIP-1 on the cell surface are the
live but still responding cancer cells, albeit such cells are less
potent in proliferation and more susceptible to subsequent
radiation treatment. Although it still under investigation to
understand the mechanism and biological consequence of the
radiation-induced TIP-1 translocation, these data support one
conclusion that the radiation-inducible translocation of TIP-1
onto the cell surface holds promise as one surrogate biomarker in
assessing the tumor responsiveness to ionizing radiation.
Discovery of the TIP-1 translocation onto the cell surface as one
biomarker of tumor response to radiation took advantages of
phage display technologies. Firstly, a peptide HVGGSSV was
identified with selective binding to the tumors responding to IR
and tyrosine kinase inhibitors with in vivo phage display [13].
Cancer cell distinguishes itself from the normal cell by expressing
proteins or receptor on the cell surface, imaging of such surface
proteins such as EGFR has been studied to track the tumor
progression or even monitor tumor response to treatment [4]. We
envision that the treatment-inducible protein expression on the
cancer cell surface holds promise as surrogate biomarkers for
imaging-based assessment of the tumor responsiveness to treat-
ment. Compared to the genomic and proteomic profiling [23] that
focus on the gene structure and overall expression abundance, in
vivo phage display prefers the molecule that are localized on the
cell surface and circulation accessible. Moreover, unlike the
subcellular proteomic profiling [24] that has been explored in
biomarker discovery in vivo, the in vivo phage display takes
advantages of the minimal sample bias and the real time in vivo
binding within the sophisticated tissues and cell structures.
Secondly, TIP-1 was identified as the molecular target of the
HVGGSSV peptide through biopanning a phage-displayed cDNA
library. In the effort to identify the molecular target(s) of the
HVGGSSV peptide, no meaningful data was generated through
BLAST search for homologous sequences [11], affinity purifica-
tion accompanied with mass spectrometric identification [9], or
yeast-two hybrid screening of cDNA libraries [8]. Low affinity or
(counted as 1). E: Western blot analysis of TIP-1 expression within the TIP-1 positive or negative cells that were sorted from the irradiated (5 Gy) H460
cells 24 hours after the irradiation. Relative TIP-1 protein level was normalized to that of the actin control (counted as 1) and shown under the image.
F: Flow cytometric profile of TIP-1 expression on the cell surface of LLC, H460 or HUVEC cells. The cells were treated with 5 Gy of X-ray, TIP-1 on the
cell surface was profiled 24 hours post the radiation treatment. Fold change of the TIP-1 positive cells was calculated by comparison to the untreated
cells (counted as 1). * p,0.01, n=3, the Student’s t-test, each was compared to the untreated control, respectively.
doi:10.1371/journal.pone.0012051.g004
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contribute to the difficulty in identification of the molecular
target(s) of the short peptide. A phage-displayed cDNA library was
screened against the HVGGSSSV peptide, rounds of biological
amplification and affinity selection significantly enriched the
peptide-binding clones that lead to the TIP-1 identification. This
study further demonstrated the potentials of screening phage-
displayed cDNA library in discovery of molecular targets of the
peptides with simple structure and low affinity.
TIP-1 is ubiquitously expressed within multiple organs [25]. It is
predominantly localized in the cytoplasma [25,26], with rare or
undetectable expression in the nucleus or on the cell plasma
membrane under normal culturing condition. It has been studied
as a PDZ antagonist in modulating cell proliferation, polarity,
Figure 5. The TIP-1 translocation onto the cell surface is one biomarker other than those for the cell death and apoptosis. A: Flow
cytometric profile of TIP-1 expression on the cell surface, apoptosis (Annexin V) and cell death or membrane integrity (PI) at 24 hours after the
radiation (5 Gy) treatment of the H460 cells. Percentage of the cells in each section was shown in the representative profile images from three
independent experiments. B: Colony formation on petri dishes of the TIP-1 positive and negative cells sorted from the irradiated H460 cells. The H460
cells were irradiated at 5 Gy. The TIP-1 positive and negative cells were sorted 24 hours post the radiation treatment. Colony formation capability of
the two subgroups of cells was shown as colony number per 1000 seeded cells. C: Proliferation capability of the sorted cells as determined with Ki-67
staining. Percentage of the proliferative cells among the counted cells was shown. D: Susceptibility of the sorted H460 cells to subsequent irradiation.
Shown are data from clonogenic assays. Survival fractions were presented to show difference of the radiation susceptibility between the TIP-1
positive and negative cells. * P,0.05, n=3, the Student’s t-test.
doi:10.1371/journal.pone.0012051.g005
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biological functions in cancer biology and cell stress response are
still under investigation. Our flow cytometry and cell imaging data
showed that the TIP-1 translocation onto the cell surface after X-
ray irradiation was dominantly observed in cancer cells, but did
not extend to endothelial cells as tested in this study by the use of
HUVEC (Fig. 4F). This difference is not related to the abundance
of the TIP-1 protein within the cells. Western blot analysis of TIP-
1 expression within the whole cell lysates indicated that TIP-1 was
expressed in all the cell lines including the HUVEC with
comparable protein level (data not shown). Tissue staining also
showed that the intravenously administrated TIP-1 antibody was
dominantly associated to the tumors cells (Fig. 3B). These data
suggested that the radiation-induced TIP-1 translocation onto the
cell surface might be limited to the tumor cells. This conclusion is
also supported by our previous observations that the HVGGSSV
peptide did not bind to normal tissues that had been irradiated or
inflamed with LPS and TNF-a [13]. Contradictorily, radiation-
induced translocation of other intracellular proteins such as P-
Selectin [28] and intercellular adhesion molecule-1 (ICAM-1) [29]
are reportedly associated with inflammatory response to ionizing
radiation and thus not specific to tumor response to the radiation
treatment. In this regard, the radiation-induced TIP-1 transloca-
tion onto the cancer cell surface is one unique biomarker of tumor
response to radiation.
Although further investigation is needed to elucidate the
mechanism(s) by which X-ray irradiation induces the TIP-1
translocation onto the cell surface and the biological relevance of
the TIP-1 translocation in the tumor response to radiation, we
revealed that the cells responding to radiation by relocating TIP-1
onto the cell surface are live but have reduced capability to
proliferate and form colonies. The cells with TIP-1 expression on
the cell surface are more susceptible to subsequent radiation
treatment, compared to the counterparts of the cells without TIP-1
expression on the cell surface. These data partially explains why
TIP-1 imaging with the HVGGSSV peptide is predictive in
assessing the tumor responsiveness to radiation [13]. The TIP-1
translocation was detectable in the first few hours after radiation
treatment and before the onset of the treatment associated
apoptosis and cell death, suggesting a potential mechanism to
assess tumor response to IR at an early time point of a treatment
course.
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